ThermoGenesis Holdings, Inc. develops, commercializes, and markets a range of automated technologies for chimeric antigen receptor (CAR-T) and other cell-based therapies. It markets a suite of solutions for automated clinical biobanking, point-of-care applications, and automation for immuno-oncology, including its semi-automated, functionally closed CAR-TXpress platform, which streamlines the manufacturing process for the emerging CAR-T immunotherapy market. The company manufactures and markets AXP II Automated Cell Separation System, an automated cell separation system for isolating and retrieving stem, and progenitor cells from umbilical cord blood; and BioArchive Automated Cryopreservation System, an automated, robotic, liquid nitrogen controlled-rate-freezing, and cryogenic storage system for cord blood samples and cell therapeutic products used in clinical applications. It offers PXP Point-of-Care System, an automated sterile system for the automated processing of autologous peripheral blood or bone marrow aspirate derived stem cells at the point-of-care, such as surgical centers or clinics; PXP-LAVARE System, an automated system designed to wash, re-suspend, and volume reduce cell suspensions; PXP-1000 System, an automated system for fast and reproducible separation of multiple cellular components from blood with minimal red blood cell contamination; and X-Series products, such as X-Lab for cell isolation, X-Wash System for cell washing and reformulation, X-Mini for small scale cell purification, and X-BACS System under development for large scale cell purification. It also provides CAR-TXpress Platform that addresses the critical unmet need for large scale cellular processing and chemistry, manufacturing, and controls needs. The company was formerly known as Cesca Therapeutics Inc. and changed its name to ThermoGenesis Holdings, Inc. in November 2019. ThermoGenesis Holdings, Inc. was incorporated in 1986 and is headquartered in Rancho Cordova, California.
IPO Year:
Exchange: NASDAQ
Website: thermogenesis.com
NT 10-Q - ThermoGenesis Holdings, Inc. (0000811212) (Filer)
8-K - ThermoGenesis Holdings, Inc. (0000811212) (Filer)
8-K - ThermoGenesis Holdings, Inc. (0000811212) (Filer)
8-K - ThermoGenesis Holdings, Inc. (0000811212) (Filer)
8-K - ThermoGenesis Holdings, Inc. (0000811212) (Filer)
8-K - ThermoGenesis Holdings, Inc. (0000811212) (Filer)
8-K - ThermoGenesis Holdings, Inc. (0000811212) (Filer)
8-K - ThermoGenesis Holdings, Inc. (0000811212) (Filer)
8-K - ThermoGenesis Holdings, Inc. (0000811212) (Filer)
10-Q - ThermoGenesis Holdings, Inc. (0000811212) (Filer)
BOSTON, July 27 2022 Appointment aligns with recognized high growth potential for INNOVO® in the US.A strong endorsement for the scientific and clinical credibility of INNOVO® as an accessible treatment for Stress Urinary Incontinence (SUI).Endorses FemTech as a high potential investment category./PRNewswire/ -- Today Atlantic Therapeutics, a Galway, Ireland and Boston, USA-based MedTech innovator, announces the appointment of Russell Medford MD, PhD as Chairman. The addition of Dr Medford to the Board is a significant step to fulfill the potential of the INNOVO® brand in the large and under-served US stress urinary incontinence (SUI) market. Dr Medford is a senior healthcare and life scien
SC 13D/A - ThermoGenesis Holdings, Inc. (0000811212) (Subject)
SC 13D/A - ThermoGenesis Holdings, Inc. (0000811212) (Subject)
SC 13D/A - ThermoGenesis Holdings, Inc. (0000811212) (Subject)
SC 13D/A - ThermoGenesis Holdings, Inc. (0000811212) (Subject)
SC 13D/A - ThermoGenesis Holdings, Inc. (0000811212) (Subject)
SC 13D/A - ThermoGenesis Holdings, Inc. (0000811212) (Subject)
SC 13D/A - ThermoGenesis Holdings, Inc. (0000811212) (Subject)
SC 13D/A - ThermoGenesis Holdings, Inc. (0000811212) (Subject)
4 - ThermoGenesis Holdings, Inc. (0000811212) (Issuer)
4 - ThermoGenesis Holdings, Inc. (0000811212) (Issuer)
4 - ThermoGenesis Holdings, Inc. (0000811212) (Issuer)
4 - ThermoGenesis Holdings, Inc. (0000811212) (Issuer)
3 - ThermoGenesis Holdings, Inc. (0000811212) (Issuer)
3 - ThermoGenesis Holdings, Inc. (0000811212) (Issuer)
4 - ThermoGenesis Holdings, Inc. (0000811212) (Issuer)
3 - ThermoGenesis Holdings, Inc. (0000811212) (Issuer)
3 - ThermoGenesis Holdings, Inc. (0000811212) (Issuer)
4 - ThermoGenesis Holdings, Inc. (0000811212) (Issuer)
Conference Call to be Held Today at 1:30 p.m. PT/4:30 p.m. ET RANCHO CORDOVA, Calif., Nov. 13, 2023 /PRNewswire/ -- ThermoGenesis Holdings, Inc. (NASDAQ:THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, today reported financial and operating results for the third quarter ended September 30, 2023, and provided a corporate business update. "In October, we were pleased to have completed the build-out of our 35,500+ square foot, state-of-the-art facility in Sacramento, which represents the cornerstone of our planned business expansion into a high performance, integrated contract development and manufacturing organization (CDMO) in the cel
Conference Call to be Held Today at 1:30 p.m. PT/4:30 p.m. ET RANCHO CORDOVA, Calif., Aug. 10, 2023 /PRNewswire/ -- ThermoGenesis Holdings, Inc. (NASDAQ:THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, today reported financial and operating results for the second quarter ended June 30, 2023, and provided a corporate business update. "Throughout the second quarter, we continued to make headway in constructing our innovative ReadyStart suites in Sacramento. The suites, to be housed in a cutting-edge 35,500+ square foot, cGMP facility, are paramount to our strategy of becoming a high-performance, integrated contract development and manuf
Conference Call to be Held on August 10, 2023 RANCHO CORDOVA, Calif., Aug. 8, 2023 /PRNewswire/ -- ThermoGenesis Holdings, Inc. (NASDAQ:THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, today announced that the Company will release its financial results for the second quarter ended June 30, 2023, and provide a corporate strategic update on Thursday, August 10, 2023, after the close of trading. A conference call and webcast will follow at 1:30 p.m. PT/ 4:30 p.m. ET. To participate in the conference call, please dial 1-844-889-4331 (domestic), 1-412-380-7406 (international) or 1-866-605-3852 (Canada). To access a live webcast of the call
Conference Call to be Held Today at 1:30 p.m. PT/4:30 p.m. ET RANCHO CORDOVA, Calif., May 15, 2023 /PRNewswire/ -- ThermoGenesis Holdings, Inc. (NASDAQ:THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, today reported financial and operating results for the first quarter ended March 31, 2023 and provided a corporate strategic update. "During the first quarter, we continued to make progress in building out our 35,500+ square foot state-of-the-art facility in Sacramento, which is a significant part of our transition into a high performance, integrated contract development and manufacturing organization ("CDMO") in the cell and gene therap
Conference Call to be Held on May 15, 2023 RANCHO CORDOVA, Calif., May 10, 2023 /PRNewswire/ -- ThermoGenesis Holdings, Inc. (NASDAQ:THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, today announced that the Company will release its financial results for the first quarter ended March 31, 2023 and provide a corporate strategic update on Monday, May 15, 2023, after the close of trading. A conference call and webcast will follow at 1:30 p.m. PT/ 4:30 p.m. ET. To participate in the conference call, please dial 1-844-889-4331 (domestic), 1-412-380-7406 (international) or 1-866-605-3852 (Canada). To access a live webcast of the call, please
Conference Call to be Held Today at 1:30 p.m. PT/4:30 p.m. ET RANCHO CORDOVA, Calif., March 30, 2023 /PRNewswire/ -- ThermoGenesis Holdings, Inc. (NASDAQ:THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, today reported financial and operating results for the year ended December 31, 2022 and provided a corporate strategic update. "We are transforming ThermoGenesis from a medical device company to a contract development and manufacturing organization ("CDMO") in the cell gene therapy field," commented Chris Xu, Ph.D., Chief Executive Officer of ThermoGenesis. "Our proprietary cell processing technologies, such as the CAR-TXpress™ platfor
Conference Call to be Held on March 30, 2023 RANCHO CORDOVA, Calif., March 28, 2023 /PRNewswire/ -- ThermoGenesis Holdings, Inc. (NASDAQ:THMO), a market leader in automated cell processing and point-of-care, autologous cell-based therapies, today announced that the Company will release its financial results for the year ended December 31, 2022 and provide a corporate strategic update on Thursday, March 30, 2023, after the close of trading. A conference call and webcast will follow at 1:30 p.m. PT/ 4:30 p.m. ET. To participate in the conference call, please dial 1-844-889-4331 (domestic), 1-412-380-7406 (international) or 1-866-605-3852 (Canada). To access a live webcast of the call, please v
Conference Call to be Held on November 10, 2022 RANCHO CORDOVA, Calif., Nov. 7, 2022 /PRNewswire/ -- ThermoGenesis Holdings, Inc. (NASDAQ:THMO), a market leader in automated cell processing and point-of-care, autologous cell-based therapies, today announced that the Company will release its financial results for the third quarter ended September 30, 2022, and provide a corporate strategic update on Thursday, November 10, 2022. A conference call and webcast will follow at 1:30 p.m. PT/ 4:30 p.m. ET. To participate in the conference call, please dial 1-844-889-4331 (domestic), 1-412-380-7406 (international) or 1-866-605-3852 (Canada). To access a live webcast of the call, please visit: https:/
Driven by Sales of the AXP, Total Revenues for the Quarter Rose 38% Compared to Prior Year Conference Call to be Held Today at 12:00 p.m. PT/3:00 p.m. ET RANCHO CORDOVA, Calif., Aug. 11, 2022 /PRNewswire/ -- ThermoGenesis Holdings, Inc. (NASDAQ:THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, today reported financial and operating results for the second quarter ended June 30, 2022 and provided a corporate strategic update. "Clinical trials for CAR-T and other next-generation cell and gene therapeutics have continued unabated, while the industry continues to grapple with high manufacturing costs and serious capacity limits created by
Conference Call to be Held on August 11, 2022 RANCHO CORDOVA, Calif., Aug. 9, 2022 /PRNewswire/ -- ThermoGenesis Holdings, Inc. (NASDAQ:THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, today announced that the Company will release its financial results for the second quarter ended June 30, 2022 and provide a corporate strategic update on Thursday, August 11, 2022. A conference call and webcast will follow at 12:00 p.m. PT/ 3:00 p.m. ET. To participate in the conference call, please dial 1-844-889-4331 (domestic), 1-412-380-7406 (international) or 1-866-605-3852 (Canada). To access a live webcast of the call, please visit: https://ther
Conference Call to be Held Today at 1:30 p.m. PT/4:30 p.m. ET RANCHO CORDOVA, Calif., Nov. 13, 2023 /PRNewswire/ -- ThermoGenesis Holdings, Inc. (NASDAQ:THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, today reported financial and operating results for the third quarter ended September 30, 2023, and provided a corporate business update. "In October, we were pleased to have completed the build-out of our 35,500+ square foot, state-of-the-art facility in Sacramento, which represents the cornerstone of our planned business expansion into a high performance, integrated contract development and manufacturing organization (CDMO) in the cel
RANCHO CORDOVA, Calif., Sept. 6, 2023 /PRNewswire/ -- ThermoGenesis Holdings, Inc. (NASDAQ:THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, today announced that Chris Xu, Ph.D., Chief Executive Officer, will present a company overview on Wednesday, September 13, at 4:30 pm ET, during the H.C. Wainwright 25th Annual Global Investment Conference, taking place September 11-13, 2023, in New York. Dr. Xu will also host in-person and virtual one-on-one meetings during the event. Institutional investors who are registered for the conference can log into www.hcwevents.com to request a meeting with the company. Those interested in meeting wit
Conference Call to be Held Today at 1:30 p.m. PT/4:30 p.m. ET RANCHO CORDOVA, Calif., Aug. 10, 2023 /PRNewswire/ -- ThermoGenesis Holdings, Inc. (NASDAQ:THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, today reported financial and operating results for the second quarter ended June 30, 2023, and provided a corporate business update. "Throughout the second quarter, we continued to make headway in constructing our innovative ReadyStart suites in Sacramento. The suites, to be housed in a cutting-edge 35,500+ square foot, cGMP facility, are paramount to our strategy of becoming a high-performance, integrated contract development and manuf
Conference Call to be Held on August 10, 2023 RANCHO CORDOVA, Calif., Aug. 8, 2023 /PRNewswire/ -- ThermoGenesis Holdings, Inc. (NASDAQ:THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, today announced that the Company will release its financial results for the second quarter ended June 30, 2023, and provide a corporate strategic update on Thursday, August 10, 2023, after the close of trading. A conference call and webcast will follow at 1:30 p.m. PT/ 4:30 p.m. ET. To participate in the conference call, please dial 1-844-889-4331 (domestic), 1-412-380-7406 (international) or 1-866-605-3852 (Canada). To access a live webcast of the call
RANCHO CORDOVA, Calif., July 17, 2023 /PRNewswire/ -- ThermoGenesis Holdings, Inc. (NASDAQ:THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, today announced the appointments of Biao Xi, Ph.D. and James Xu, Esq., DBA, PsyD., J.D., CPA to its Board, effective July 17, 2023. Both are independent directors. The appointments expand ThermoGenesis' Board to seven members. "Biao is a highly regarded life science executive with extensive experience in biopharmaceutical research and drug development and James brings strong legal and business acumen, including more than 25 years in the field of patent, corporate and tax law. Together, their exper
Conference Call to be Held Today at 1:30 p.m. PT/4:30 p.m. ET RANCHO CORDOVA, Calif., May 15, 2023 /PRNewswire/ -- ThermoGenesis Holdings, Inc. (NASDAQ:THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, today reported financial and operating results for the first quarter ended March 31, 2023 and provided a corporate strategic update. "During the first quarter, we continued to make progress in building out our 35,500+ square foot state-of-the-art facility in Sacramento, which is a significant part of our transition into a high performance, integrated contract development and manufacturing organization ("CDMO") in the cell and gene therap
Conference Call to be Held on May 15, 2023 RANCHO CORDOVA, Calif., May 10, 2023 /PRNewswire/ -- ThermoGenesis Holdings, Inc. (NASDAQ:THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, today announced that the Company will release its financial results for the first quarter ended March 31, 2023 and provide a corporate strategic update on Monday, May 15, 2023, after the close of trading. A conference call and webcast will follow at 1:30 p.m. PT/ 4:30 p.m. ET. To participate in the conference call, please dial 1-844-889-4331 (domestic), 1-412-380-7406 (international) or 1-866-605-3852 (Canada). To access a live webcast of the call, please
Conference Call to be Held Today at 1:30 p.m. PT/4:30 p.m. ET RANCHO CORDOVA, Calif., March 30, 2023 /PRNewswire/ -- ThermoGenesis Holdings, Inc. (NASDAQ:THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, today reported financial and operating results for the year ended December 31, 2022 and provided a corporate strategic update. "We are transforming ThermoGenesis from a medical device company to a contract development and manufacturing organization ("CDMO") in the cell gene therapy field," commented Chris Xu, Ph.D., Chief Executive Officer of ThermoGenesis. "Our proprietary cell processing technologies, such as the CAR-TXpress™ platfor
Conference Call to be Held on March 30, 2023 RANCHO CORDOVA, Calif., March 28, 2023 /PRNewswire/ -- ThermoGenesis Holdings, Inc. (NASDAQ:THMO), a market leader in automated cell processing and point-of-care, autologous cell-based therapies, today announced that the Company will release its financial results for the year ended December 31, 2022 and provide a corporate strategic update on Thursday, March 30, 2023, after the close of trading. A conference call and webcast will follow at 1:30 p.m. PT/ 4:30 p.m. ET. To participate in the conference call, please dial 1-844-889-4331 (domestic), 1-412-380-7406 (international) or 1-866-605-3852 (Canada). To access a live webcast of the call, please v
RANCHO CORDOVA, Calif., March 20, 2023 /PRNewswire/ -- ThermoGenesis Holdings, Inc. (NASDAQ:THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, today announced the closing of its previously announced purchase and sale of 1,071,429 shares of its common stock (or common stock equivalents) and warrants to purchase up to 1,071,429 shares of its common stock at a purchase price of $2.80 per share of common stock (or common stock equivalent) and associated warrant in a private placement priced at-the-market under Nasdaq rules. The warrants have an exercise price of $2.65 per share, are exercisable immediately upon issuance and expire five and
Shares of AMMO, Inc. (NASDAQ:POWW) fell sharply during Friday's session following fourth-quarter results. AMMO reported a fourth-quarter profit of 1 cent per share, compared to market expectations for a loss of 1 cent per share. The company reported quarterly sales of $40.42 million topping estimates of $37.90 million, according to data from Benzinga Pro. AMMO shares dipped 19.1% to $2.0306 on Friday. Here are some other stocks moving in today’s mid-day session. Gainers Kaival Brands Innovations Group, Inc. (NASDAQ:KAVL) shares jumped 345% to $6.06. SRIVARU Holding Limited (NASDAQ:SVMH) gained 150% to $0.3852 after the company announced it will begin accepting paid reserva
U.S. stocks traded higher toward the end of trading, with the S&P 500 surging around 1% on Wednesday. The Dow traded up 0.06% to 38,771.21 while the NASDAQ rose 1.77% to 17,651.35. The S&P 500 also rose, gaining, 1.03% to 5,430.69. Check This Out: General Motors, Toll Brothers And 2 Other Stocks Insiders Are Selling Leading and Lagging SectorsInformation technology shares jumped by 3% on Wednesday. In trading on Wednesday, consumer staples shares fell by 1%. Top Headline The EIA said stocks of crude oil in the U.S. climbed by 3.730 million barrels in the week ending June 7, versus market expectations for a 1.55 million barrels decline. Equities Trading UP
Shares of Streamline Health Solutions, Inc. (NASDAQ:STRM) fell sharply during Wednesday's session after the company reported worse-than-expected first-quarter EPS results. Streamline Health reported quarterly losses of 5 cents per share which missed the analyst consensus estimate of 4 cents per share. The company reported quarterly sales of $4.33 million which beat the analyst consensus estimate of $4.31 million, according to data from Benzinga Pro. Streamline Health Solutions shares dipped 23.3% to $0.4902 on Wednesday. Here are some other stocks moving in today’s mid-day session. Gainers DDC Enterprise Limited (NYSE:DDC) surged 101% to $1.04. DDC Enterprise said it has acqu
Gainers Longeveron (NASDAQ:LGVN) shares rose 112.1% to $1.74 during Wednesday's regular session. The market value of their outstanding shares is at $11.0 million. vTv Therapeutics (NASDAQ:VTVT) stock increased by 43.09% to $26.0. The market value of their outstanding shares is at $63.2 million. Avidity Biosciences (NASDAQ:RNA) shares increased by 32.32% to $38.27. The company's market cap stands at $3.6 billion. Cyclerion Therapeutics (NASDAQ:CYCN) stock rose 30.39% to $2.96. The company's market cap stands at $7.3 million. Telesis Bio (NASDAQ:TBIO) stock moved upwards by 22.53% to $3.86. The company's market cap stands at $6.4 million. Autonomix Medical (NASDAQ:AMIX) stock rose 20.94%
U.S. stocks traded higher midway through trading, with the Nasdaq Composite surging more than 300 points on Wednesday. The Dow traded up 0.65% to 38,997.91 while the NASDAQ rose 1.82% to 17,659.08. The S&P 500 also rose, gaining, 1.27% to 5,443.32. Check This Out: General Motors, Toll Brothers And 2 Other Stocks Insiders Are Selling Leading and Lagging SectorsInformation technology shares jumped by 2.6% on Wednesday. In trading on Wednesday, utilities shares fell by 0.5%. Top Headline Shares of Oracle Corporation (NYSE:ORCL) jumped over 11% on Wednesday after the company reported fourth-quarter financial results. Oracle reported fourth-quarter revenue of $14.3 billion,
U.S. stocks traded higher this morning, with the Dow Jones index gaining more than 300 points on Wednesday. Following the market opening Wednesday, the Dow traded up 0.84% to 39,072.22 while the NASDAQ rose 0.87% to 17,494.72. The S&P 500 also rose, gaining, 0.84% to 5,420.33. Check This Out: General Motors, Toll Brothers And 2 Other Stocks Insiders Are Selling Leading and Lagging SectorsReal estate shares jumped by 2.1% on Wednesday. In trading on Wednesday, consumer staples shares rose by just 0.1%. Top Headline The annual CPI inflation rate fell from 3.4% to 3.3% in May, below than the median economist projection of 3.4%. According to Econoday, the economist consensus ra
ThermoGenesis Holdings Inc (NASDAQ:THMO) shares are trading lower by 41% to $0.33 during Wednesday's session after the Nasdaq denied the company’s request for continued listing and the stock will be suspended at the opening of business on June 17. What Happened? On April 19, ThermoGenesis was notified by Nasdaq that its stockholders’ equity did not meet the minimum $2.5 million required for continued listing. As of the report date, the company also did not meet alternative Nasdaq requirements for market value or net income. On June 6 Nasdaq denied the company’s request for continued listing, citing a lack of a definitive plan for compliance. As a result, trading of the company’s sto
Gainers Avidity Biosciences (NASDAQ:RNA) shares rose 24.5% to $36.0 during Wednesday's pre-market session. The company's market cap stands at $3.4 billion. Molecular Partners (NASDAQ:MOLN) shares moved upwards by 18.43% to $5.91. The market value of their outstanding shares is at $196.1 million. Longeveron (NASDAQ:LGVN) shares increased by 15.84% to $0.95. The company's market cap stands at $6.0 million. TRACON Pharma (NASDAQ:TCON) shares increased by 15.74% to $1.25. The market value of their outstanding shares is at $3.3 million. Oramed Pharmaceuticals (NASDAQ:ORMP) stock moved upwards by 14.49% to $2.37. The market value of their outstanding shares is at $96.2 million. NovaBay Pharm
Shares of Oracle Corporation (NYSE:ORCL) rose sharply in today's pre-market trading after the company reported fourth-quarter financial results. Oracle posted weaker-than-expected earnings for its fiscal fourth quarter. The company also announced a partnership with Alphabet Inc’s (NASDAQ:GOOGL) (NASDAQ:GOOG) Google Cloud. Oracle shares jumped 9% to $135.00 in the pre-market trading session. Here are some other stocks moving in pre-market trading. Gainers Golden Heaven Group Holdings Ltd (NASDAQ:GDHG) rose 70.3% to $0.3049 in today's pre-market trading. WANG & LEE GROUP, Inc. (NASDAQ:WLGS) shares rose 43.1% to $0.8760 in pre-market trading after surging 16% on Tuesday. S